Should immunosuppression be used to improve #PAH in #SSc added to PAH Rx (85%) Morbidity or mortality outcomes >700 pts - half had a DMARD after dx RheumNow #EULAR2023 OP0238 Targeted Rx improved esp RTX\TCZ findings V interesting results #GameChanger May change my Rx practice!

Retro French database study shows reassuring data. Overall mortality after IRAEs =similar between pts receiving b/tsDMARDs vs. those who don't 70000+ pts treated w/ ICI, 7800+ IRAEs (most frequent colitis) & 330 treated w/ b/tsDMARDs, 10% Rheum IRAE OP0270 @RheumNow #EULAR23 https://t.co/OFNaIU4kzt

Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in 1 year, with higher adherence with age, SLE and socioeconomic class, Hoque MR, Abst#0222 #EULAR2023 @RheumNow https://t.co/Bld5kWVQxE

Fatigue in SLE remains a challenge! Online digital tool - LEAF - Lupus Expert System for Assessment of Fatigue - assement of fatigue PROMs in 1250pts - 80% reported fatigue, 93% found tool helpful @rheumnow #EULAR2023 Need more tools to assess and manage fatigue! abst#OP0230

#EULAR2023 #POS1075 Which biologics have the lowest retention rate in Elderly patients (=>65 yrs) in Rheumatoid Arthritis? Data from Italian registry showed 1/3 discontinued biologics at 2 yrs. IL6-i: lowest persistence; Abatacept: highest @RheumNow https://t.co/28n4qzR3aM

Can’t escape ORAL Surveillance RCT talk Lots of real world data on CV risk & JAKi here (with all the selection, measurement bias) First up: multinational JAK-pot study (n=>50k) Even if you mirror the high-risk RCT cohort - not much there for MACE OP0219 #EULAR2023 @RheumNow https://t.co/FfNspdivri

No new predictors for decline in #SSc lung function in ILD Progression of #scleroderma Lung disease is common - risks male, dcSSc, low FVC, Topo1 ⁦@RheumNow⁩ #EULAR2023, OP0236 ⁦@eular_org⁩ https://t.co/bTxTyLE8dZ

An AI algorithm to predict opined related deaths UK database >1000000 pts, 1200+ opioids related deaths Risk factors: Substance used disorder Hx self harm Alcohol abuse Oxycodone Liver disease Concomitant gabapentinoids & BZD *no pictures allowed* @Rheumnow OP0269 #EULAR23 https://t.co/II96fnhqy3

JAKi use did not increase CV risk compared to TNF, no difference between Bari and Tofa, non significant increased IRR in patients >65 years, Merel Opdam, Abst#OP0221 #EULAR2023 @RheumNow https://t.co/Pu5X8RHJOY

#Deeplearning in salivary biopsies in #SjogrensSyndrome - 327 pts - binary focus score (>=1) prediction the AUROC was 0.87 and for primary sjogrens diagnosis prediction it was 0.84 Quicker and cost effective in the future? @rheumnow #EULAR2023 abst#OP0232 https://t.co/Ec0zuKqpXf

So we need protocolized extra steroids in new RA? A debate as old as time Individual patient data metaanalysis - slight gains early on, not sustained - fewer DMARD changes - but a heap more PNL, well after the protocol ends Life is about trade-offs😐 OP0220 #EULAR2023 @RheumNow https://t.co/M8SBKjGncv

#EULAR2023 #POS1066 “Diagnosis: Seropositive Nodular Rheumatoid Arthritis” - I can probably get rid of Nodular soon in my letter. Trends of Nodules have decreased over time. Could be because we are getting better at preventing erosion and smoking cessation @RheumNow https://t.co/fmQvyNHCUJ

Impact of menopause & on function in RA HAQ increases slightly after menopause Premature menopause = worse function Slightly better HAQ (but moderate & no effects on other PROs) in THR group vs. non THR No safety data @RheumNow OP0268 #EULAR23 https://t.co/7KJScF8O2X

Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w